Acute Myocarditis Associated With Desmosomal Gene Variants.
Enrico Ammirati, Francesca Raimondi, Nicolas Piriou...
https://pubmed.ncbi.nlm.nih.gov/36175056/Actively Recruiting
Led by Niguarda Hospital · Updated on 2026-04-20
80
Participants Needed
10
Research Sites
104 weeks
Total Duration
Researchers are evaluating colchicine as a treatment for patients with chronic inflammatory cardiomyopathy Infl-CMP, a heart condition caused by inflammation of the heart muscle that can lead to dangerous heart rhythm problems and heart failure. This phase III trial also includes a registry to study the role of genetic factors in the disease. The trial aims to find out if colchicine can reduce inflammation and improve heart function compared to placebo, especially considering patients genetic backgrounds. In this randomized, single-blinded, multi-center trial, patients with Infl-CMP will receive colchicine at doses of 0.5 to 1 mg daily or placebo tablets for 6 months. The study includes patients with signs of heart inflammation confirmed by imaging tests like cardiac MRI or PET scans, along with specific heart rhythm abnormalities or reduced heart pumping ability. A prospective registry will follow additional patients to explore the impact of genetic testing on disease outcomes. Blood and tissue samples will also be studied to understand the underlying molecular mechanisms. Participants will undergo regular assessments over the 6-month treatment period, including imaging tests, heart rhythm monitoring, blood tests, and evaluations of symptoms and quality of life. Researchers will measure whether patients remain alive without disease worsening and look for improvements in heart imaging or arrhythmia burden. Safety monitoring and follow-up will continue through the trial, with results aimed at guiding future personalized treatments for Infl-CMP.
CONDITIONS
CMP-MYTHiC Trial and Registry - CardioMyoPathy With MYocarditis THerapy With Colchicine
E
Enrico Ammirati, MD, PhD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Niguarda Hospital
Lead Sponsor
European Union
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 6 months
Participants receive either colchicine or placebo daily to assess the effect on inflammatory cardiomyopathy symptoms and heart function.
Regular visits during treatment to monitor response and safety
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Enrico Ammirati, Francesca Raimondi, Nicolas Piriou...
https://pubmed.ncbi.nlm.nih.gov/36175056/Enrico Ammirati, Iside Cartella, Michele Ciabatti...
https://pubmed.ncbi.nlm.nih.gov/41730291/Andrea Stoehr, Christiane Neuber, Christina Baldauf...
https://pubmed.ncbi.nlm.nih.gov/24585781/Enrico Ammirati, Maria Frigerio, Eric D Adler...
https://pubmed.ncbi.nlm.nih.gov/33176455/Amrit S Lota, Mark R Hazebroek, Pantazis Theotokis...
https://pubmed.ncbi.nlm.nih.gov/36154167/Dhanunjaya Lakkireddy, Mohit K Turagam, Bharath Yarlagadda...
https://pubmed.ncbi.nlm.nih.gov/31838913/Jean-Claude Tardif, Simon Kouz, David D Waters...
https://pubmed.ncbi.nlm.nih.gov/31733140/Jessica Artico, Marco Merlo, Giulia Delcaro...
https://pubmed.ncbi.nlm.nih.gov/32553263/Enrico Ammirati, Javid J Moslehi
https://pubmed.ncbi.nlm.nih.gov/37014337/Amy R Kontorovich, Nihir Patel, Arden Moscati...
https://pubmed.ncbi.nlm.nih.gov/34368507/Niguarda Hospital
Lead Sponsor
European Union
Collaborating Sponsor